Catalent Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Catalent Inc 's ROA in the first quarter of 2025?
Catalent Inc recorded a cumulative net loss of $-413 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -4.23%.

However, within the Healthcare sector 239 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 3092, from total ROA ranking in the fourth quarter of 2024 at 3419.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) I. Quarter	(Jun 30 2024) IV. Quarter	(Mar 31 2024) III. Quarter	(Dec 31 2023) II. Quarter	(Sep 30 2023) I. Quarter
Y / Y Total Assets Change	5.21 %	-3.14 %	-11.88 %	-8.78 %	-10.4 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-413	-1,043	-1,176	-1,302	-1,015
Return On Assets (TTM)	-4.23 %	-10.82 %	-12.1 %	-12.99 %	-9.89 %
CTLT's Total Ranking	# 3092	# 3419	# 3525	# 4095	# 3516
Total Assets (TTM) in million	10,508	9,708	8,986	9,879	9,988
Seq. Total Assets Change	8.24 %	8.03 %	-9.04 %	-1.09 %	-0.35 %
Seq. Net Income Change	-	-	-	-	-

CTLT's 5 Years Annual ROA >> Back to CTLT Management Effectiveness >> Compare CTLT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 78
Sector	# 240
Overall	# 3041

Return On Assets Statistics
High	Average	Low
7.93 %	1.61 %	-12.51 %
(Sep 30 2015)		(Dec 31 2023)

Financial Statements
Catalent Inc 's Assets	$ 10,508 million	CTLT's Balance sheet
Catalent Inc 's Income	$ -129 million	Quarterly CTLT's Income Statement
CTLT's Income by Division		See CTLT's Income by Division

Annual Return On Assets	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021	(Jun 30 2020) FY 2020
Y / Y Total Assets Change	-9.5 %	2.56 %	15.32 %	17.17 %	25.75 %
Total Assets in million	9,753	10,777	10,508	9,112	7,777
Y / Y Net Income Change	-	-	-8.7 %	205.78 %	25.91 %
Net Income in million	-1,043	-256	483	529	173
Annual Return On Assets	-10.69 %	-2.38 %	4.6 %	5.81 %	2.22 %

CTLT's 5 Years Annual ROA >> Back to CTLT Management Effectiveness >> Compare CTLT ROA to its Competitors

More Return On Assets Ratios
CTLT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CTLT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CTLT's Competitors
Subscribers only: Roa for Catalent Inc 's Suppliers
Subscribers only: Return On Assets for CTLT's Customers

You may also want to know
CTLT's Roi	CTLT's Inventory Turnover Ratio	CTLT's Growth Rates	CTLT's Dividend Comparisons
	CTLT's Profitability Ratios	CTLT's Asset Turnover Ratio	CTLT's Dividend Growth
CTLT's Roe	CTLT's Valuation Ratios	CTLT's Financial Strength Ratios	CTLT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.